首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2014年 10期 => 肝衰竭 =>人工肝血浆置换治疗肝衰竭的临床观..
人工肝血浆置换治疗肝衰竭的临床观察
Clinical efficacy of plasma exchange therapy in treatment of liver failure
文章发布日期:2014年09月12日  来源:  作者:张琳,赵守松  点击次数:2591次  下载次数:510次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的观察血浆置换术(PE)治疗肝衰竭的疗效。方法回顾性分析2012年1月至2013年6月收治的肝衰竭患者的临床资料,PE组33例肝衰竭患者在内科综合治疗基础上加用血浆置换治疗,对照组30例肝衰竭患者予内科综合治疗,观察两组患者治疗2周后临床症状、并发症发生情况、肝功能生化指标的变化等,随访治疗后3个月内病情转归情况并分析影响疗效的因素。实验检测数据用均数±标准差(x±s)表示,计量资料用t检验进行比较,计数资料采用χ2检验或Fisher确切概率法。结果予血浆置换治疗后,患者乏力、纳差、腹胀等临床症状明显改善,血清中ALT、TBil水平较治疗前降低[(390.48±536.52)U/L vs (81.03±47.58)U/L;(479.27±130.01)μmol/L vs (244.64±151.05)μmol/L,P值均<0.01],Alb、胆固醇(CHO)、凝血酶原活动度(PTA)水平较治疗前升高[(33.06±5.42)g/L vs (35.24±3.68)g/L;(2.50±1.24)mmol/L vs (3.59±086)mmol/L;(34.16±5.33)% vs (73.98±27.23)%,P值均<0.01],对照组治疗后ALT、TBil、Alb、CHO、PTA水平较治疗前差异无统计学意义(P>0.05);PE组患者好转率明显高于对照组(χ2=8.276,P<0.01),而病死率低于对照组(χ2=13.258,P<0.01);PE治疗效果与治疗前TBil水平、并发症、胆酶分离、年龄≥40岁有关(P<0.05),TBil、胆酶分离是影响PE疗效的独立危险因素(P<0.05,OR值分别为1.01、875);术中共发生不良反应8例次,予对症处理后均可好转并完成治疗。结论PE治疗肝衰竭安全有效,有临床推广价值。TBil、胆酶分离是影响PE疗效的独立危险因素。
【Abstract】:ObjectiveTo investigate the clinical efficacy of plasma exchange (PE) in the treatment of liver failure. MethodsA retrospective analysis was performed on the clinical data of patients with liver failure who were treated from January 2012 to June 2013 in our hospital. Thirty-three patients in PE group received PE in addition to medical comprehensive treatment, and 30 patients in control group were treated with medical comprehensive treatment. Clinical symptoms, complications, and the changes in biochemical markers of liver function were observed after 2 weeks of treatment, post-treatment outcomes were evaluated by 3-month followed-up, and the influential factors for efficacy were analyzed. Experimental data were expressed as mean ± standard deviation, continuous data were compared by t test, and categorical data were analyzed by chi-square test or Fisher′s exact test. ResultsSymptoms such as fatigue, poor appetite, and abdominal distension were significantly relieved after PE. Post-treatment serum alanine aminotransferase (ALT) and total bilirubin (TBil) levels were significantly lower compared with pre-treatment levels (390.48±536.52 U/L vs 81.03±47.58 U/L and 479.27±130.01 μmol/L vs 244.64±151.05 μmol/L, P<0.005), whereas post-treatment levels of albumin (Alb) and cholesterol (CHO) and prothrombin activity (PTA) were significantly higher than those measured before the treatment (33.06±5.42 g/L vs 35.24±3.68 g/L, 2.50±1.24 mmol/L vs 3.59±0.86 mmol/L, and 34.16%±5.33% vs 73.98%±27.23%, P<0.005). No significant differences were identified between pre- and post-treatment levels of ALT, TBil , Alb, CHO, and PTA (P>0.05). Patients in PE group had a significantly higher improvement rate (χ2=8.276, P<0.005) and a significantly lower mortality rate (χ2=13.258, P<0.005) compared with the control group. The efficacy of PE was found to be correlated with pre-treatment TBil level, complications, bilirubin enzyme separation, and age ≥40 years(P<0.05). TBil and bilirubin enzyme separation were independent risk factors affecting the efficacy of PE (P<0.05, OR=1.01 and8.75). Adverse reactions occurred in 8 cases during PE treatment, and disappeared after symptomatic treatment. ConclusionPE is a safe and effective treatment for liver failure, and holds promise for clinical application. TBil level and bilirubin enzyme separation are independent risk factors affecting the efficacy of PE.
【关键字】:肝功能衰竭;肝,人工;血浆置换
【Key words】:liver failure; liver, artifical; plasma exchange
【引证本文】:

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号